Table 4.
Univariate and Multivariate Cox Regression Analysis of Overall and Disease-free Survival for HNRNPM (n = 370) From TCGA Database
| Exposure |
Multivariate analysis |
|||
|---|---|---|---|---|
| Overall survival |
Disease-free survival |
|||
| HR (95% CI) | P | HR (95% CI) | P | |
| HNRNPM | ||||
| Low expression | 1.0 | 1.0 | ||
| High expression | 1.8 (1.2–2.5) | .002 | 1.5 (1.1–1.9) | .005 |
| Sex | ||||
| Female | 1.0 | 1.0 | ||
| Male | 0.8 (0.6–1.2) | .252 | 0.9 (0.7–1.2) | .453 |
| Recurrence sites | ||||
| Liver | 1.0 | 1.0 | ||
| Lung | 2.9 (1.5–5.8) | .002 | 1.4 (0.8–2.3) | .194 |
| Other | 0.9 (0.4–1.7) | .674 | 0.5 (0.3–0.9) | .015 |
| AJCC stage | ||||
| I/II | 1.0 | 1.0 | ||
| III/IV | 2.5 (1.7–3.6) | < .001 | 2.1 (1.5–2.7) | < .001 |
| Tumor grade | ||||
| I | 1.0 | 1.0 | ||
| II | 1.2 (0.7–2.0) | .541 | 1.2 (0.8–1.8) | .293 |
| III/IV | 1.3 (0.7–2.2) | .400 | 1.3 (0.8–1.9) | .248 |
| Embolization performed | ||||
| No | 1.0 | 1.0 | ||
| Yes | 2.9 (0.8–9.8) | .094 | 2.7 (1.2–5.9) | .012 |
| Albumin, g/dL | 1.0 (0.9–1.0) | .547 | 1.0 (1.0–1.0) | .736 |
| Bilirubin, mg/dL | 1.0 (1.0–1.0) | .951 | 1.0 (1.0–1.0) | .176 |
| Child-Pugh grade | ||||
| A | 1.0 | 1.0 | ||
| B | 1.8 (0.7–4.5) | .238 | 1.3 (0.6–2.6) | .520 |
| Creatinine, mg/dL | 0.8 (0.5–1.2) | .263 | 1.0 (0.9–1.2) | .735 |
| Platelet count, ×104 | 1.0 (1.0–1.0) | .080 | 1.0 (1.0–1.0) | .383 |
| Prothrombin time, s | 1.0 (1.0–1.1) | .152 | 1.0 (1.0–1.1) | .548 |
| Vital status | ||||
| HBV | 1.0 | 1.0 | ||
| HCV | 0.7 (0.3–1.6) | .372 | 0.7 (0.3–1.4) | .310 |
| Ki-67 | ||||
| Low expression | 1.0 | 1.0 | ||
| High expression | 1.8 (1.2–2.5) | .001 | 1.7 (1.3–2.2) | < .001 |
Note: Boldface P values indicate statistical significance.
AJCC, American Joint Committee on Cancer; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HNRNPM, heterogeneous nuclear ribonucleoprotein M; HR, hazard ratio; TCGA, The Cancer Genome Atlas.